oasis 1 oral semaglutide 50 mg nejm 2023 obesity at a Dose of 25 in Adults with Overweight or oral semaglutide 50 mg obesity

If somebody comes in with a BMI over 30 and you dont treat it, thats Tuesday. He thinks some of the hesitancy for treating patients with obesity medications comes from the history of dangerous weight loss drugs

Microdosing GLP-1 medications lacks clinical evidence, meaning doctors dont have enough reliable data to confirm whether lower than approved doses are effective

GLP1 receptor agonists (like Semaglutide & Tirzepatide) mimic a gut hormone to curb appetite, support blood sugar control, and promote fat lossclinically shown to reduce body weight by 1522%

With proper nutrition , these issues can improve while weight loss continues safely

Silico Pharmacol

References: Prevalence and incidence of shoulder pain in the general population